Prot #MRT5005-101: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 (CO-hCFTR mRNA/ICE LNP) Administered by Nebulization to

Project: Research project

StatusActive
Effective start/end date12/7/1812/7/21

Funding

  • Rho, Inc. (Prot #MRT5005-101)
  • Translate Bio, Inc. (Prot #MRT5005-101)